SCHEMBL6433115

SCHEMBL6433115

Cc1cc(NC(=O)OC(C)(C)C)c(NC(=O)CC(=O)c2cccc(-n3ccnc3)c2)cc1C(F)(F)F

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.45
L3MBTL1 Q9Y468 4/20 0.41
F9 P00740 1/20 0.37
F10 P00742 1/20 0.37
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
KDM4D Q6B0I6 1/20 0.37
POLB P06746 1/20 0.37
BRD4 O60885 1/20 0.37
ADH5 P11766 1/20 0.35
MAPK14 Q16539 1/20 0.35
CD38 P28907 1/20 0.35
CASP6 P55212 2/20 0.35
MCL1 Q07820 2/20 0.35
CTDSP1 Q9GZU7 2/20 0.35
HDAC1 Q13547 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6434069 0.91 ABL1 (0.44) ABL1L3MBTL1F9F10PDE4A
SCHEMBL7220987 0.90 ABL1 (0.43) ABL1L3MBTL1F9F10PDE4A
SCHEMBL6164710 0.88 ABL1 (0.41) ABL1L3MBTL1F9F10PDE4A
SCHEMBL6434059 0.86 POLB (0.37) L3MBTL1POLBMAPK14
SCHEMBL6434623 0.86 NOTUM (0.39) L3MBTL1POLB
SCHEMBL7146597 0.86 ADH5 (0.41) ABL1L3MBTL1PDE4APDE4BPDE4C
SCHEMBL6435447 0.85 POLB (0.37) L3MBTL1POLB
SCHEMBL6434658 0.85 L3MBTL1 (0.45) ABL1L3MBTL1PDE4APDE4BPDE4C
SCHEMBL5868843 0.83 CYP17A1 (0.42) ABL1L3MBTL1PDE4APDE4BPDE4C
SCHEMBL5869001 0.83 PORCN (0.42) ABL1L3MBTL1PDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379522-B1 DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I HOFFMANN LA ROCHE (CH) 2005-01-26 EP disclosed
US-6548495-B2 Metabotropic glutamate receptor agonist for treatment or prevention of acute and/or chronic neurological disorders HOFFMANN-LA ROCHE INC. 2003-04-15 US disclosed
US-20020198197-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives HOFFMANN-LA ROCHE INC. 2002-12-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198197-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives BDKRB1, BDKRB2, GRIN1 ABL1 2651/4885L3MBTL1 3136/4885F9 1530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.